Evidence for ABL Amplification in Multiple Myeloma and Therapeutic Implications

Table 1

Baseline characteristics of patients with multiple myeloma.

Patient characteristics	ABL amplification (n = 67) No. (%)	Normal ABL gene (n = 34) No. (%)
Gender
Male	48 (71.6)	20 (58.8)	0.194
Female	19 (28.4)	14 (41.2)
Age (years)
<6	36 (53.7)	21 (61.8)	0.292
≥65	31 (46.3)	13 (38.2)
Median	64	60
M component
IgG	44 (65.7)	18 (52.9)	0.133
IgA	20 (29.9)	9 (26.5)
IgD	0	0
λ	1 (1.5)	3 (8.8)
κ	2 (3.0)	4 (11.8)
DS stage
I	7 (10.4)	1 (2.9)	0.476
II	4 (6.0)	2 (5.9)
III	56 (83.6)	31 (91.2)
Creatinine (μmol/L)
≤177	55 (82.1)	33 (97.1)	0.055
>177	12 (17.9)	1 (2.9)
Albumin (g/L)
≥35	5 (7.5)	7 (20.6)	0.099
<35	62 (92.5)	27 (79.4)
β2-MG (mg/L)
<3.5	19 (28.4)	16 (47.1)	0.228
3.5-5.5	26 (38.8)	9 (26.5)
≥5.5	22 (32.8)	9 (26.5)
LDH (U/L)
<250	49 (73.1)	27 (79.4)	0.475
≥250	18 (26.9)	7 (20.6)
Karyotype
Hyperdiploid	22 (32.8)	2 (5.9)	<0.001
Hypodiploid	0	6 (17.6)
Polyploidy	1 (1.50)	0
Normal karyotype	44 (65.7)	26 (76.5)
Coexistent adverse cytogenetics
c-Myc amplification	31 (46.3)	10 (29.4)	0.103
IGH rearrangement	45 (67.2)	20 (58.8)	0.408
D13S319/RB1 deletion	38 (56.7)	22 (64.7)	0.528
p53 deletion	5 (14.9)	2 (5.9)	0.768
1q21 amplification	34 (50.7)	15 (44.1)	0.440